Conversion of in vitro cultured human monocytes into effective presenters of an HER2/neu-Encoded CTL peptide epitope

K. Wasserman; M. M. Corsi; L. Szekely; K. Kono; H. H. Maes; R. Kiessling

Conversion of in vitro cultured human monocytes into effective presenters of an HER2/neu-Encoded CTL peptide epitope

K. Wasserman, M. M. Corsi, L. Szekely, K. Kono, H. H. Maes, R. Kiessling

IRCCS Policlinico San Donato

Research output: Contribution to journal › Article

Abstract

Tumour-derived peptides have been surveyed, in a variety of systems, for their ability to elicit cytokine release from class I restricted T cells. Analogous studies on ovarian carcinoma have employed the antigen-processing defective T2 cell line. Purified dendritic cells (DC) have been reported to act as highly effective APC. A facile method was developed whereby DC-like cells were generated from monocyte precursors. Herein, evidence is presented suggesting DC-like cells are superior to T2 with respect to their ability to present a defined CTL epitope associated with ovarian carcinoma.

Original language	English
Pages (from-to)	678-682
Number of pages	5
Journal	Scandinavian Journal of Immunology
Volume	45
Issue number	6
Publication status	Published - 1997

ASJC Scopus subject areas

Immunology

Access to Document

Fingerprint Dive into the research topics of 'Conversion of in vitro cultured human monocytes into effective presenters of an HER2/neu-Encoded CTL peptide epitope'. Together they form a unique fingerprint.

Cite this

@article{3cb002f43c8c4b91b4ba9c9c2dabb833,

title = "Conversion of in vitro cultured human monocytes into effective presenters of an HER2/neu-Encoded CTL peptide epitope",

abstract = "Tumour-derived peptides have been surveyed, in a variety of systems, for their ability to elicit cytokine release from class I restricted T cells. Analogous studies on ovarian carcinoma have employed the antigen-processing defective T2 cell line. Purified dendritic cells (DC) have been reported to act as highly effective APC. A facile method was developed whereby DC-like cells were generated from monocyte precursors. Herein, evidence is presented suggesting DC-like cells are superior to T2 with respect to their ability to present a defined CTL epitope associated with ovarian carcinoma.",

author = "K. Wasserman and Corsi, {M. M.} and L. Szekely and K. Kono and Maes, {H. H.} and R. Kiessling",

year = "1997",

language = "English",

volume = "45",

pages = "678--682",

journal = "Scandinavian Journal of Immunology",

issn = "0300-9475",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Conversion of in vitro cultured human monocytes into effective presenters of an HER2/neu-Encoded CTL peptide epitope

AU - Wasserman, K.

AU - Corsi, M. M.

AU - Szekely, L.

AU - Kono, K.

AU - Maes, H. H.

AU - Kiessling, R.

PY - 1997

Y1 - 1997

N2 - Tumour-derived peptides have been surveyed, in a variety of systems, for their ability to elicit cytokine release from class I restricted T cells. Analogous studies on ovarian carcinoma have employed the antigen-processing defective T2 cell line. Purified dendritic cells (DC) have been reported to act as highly effective APC. A facile method was developed whereby DC-like cells were generated from monocyte precursors. Herein, evidence is presented suggesting DC-like cells are superior to T2 with respect to their ability to present a defined CTL epitope associated with ovarian carcinoma.

AB - Tumour-derived peptides have been surveyed, in a variety of systems, for their ability to elicit cytokine release from class I restricted T cells. Analogous studies on ovarian carcinoma have employed the antigen-processing defective T2 cell line. Purified dendritic cells (DC) have been reported to act as highly effective APC. A facile method was developed whereby DC-like cells were generated from monocyte precursors. Herein, evidence is presented suggesting DC-like cells are superior to T2 with respect to their ability to present a defined CTL epitope associated with ovarian carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0030923699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030923699&partnerID=8YFLogxK

M3 - Article

C2 - 9201308

AN - SCOPUS:0030923699

VL - 45

SP - 678

EP - 682

JO - Scandinavian Journal of Immunology

JF - Scandinavian Journal of Immunology

SN - 0300-9475

IS - 6

ER -